Intrapleural administration of tumour necrosis factor alpha (TNFα) in patients with mesothelioma: Cytokine patterns and acute-phase protein response

European Journal of Clinical Investigation

Volumn 30, Issue 4, 2000, Pages 336-343

  Stam, T C ^a   Swaak, A J G ^a,b,c   Kruit, W H J ^a   Stoter, G ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c Zuiderziekenhuis   (Netherlands)

Author keywords

Acute phase response; Cytokine response; Intrapleural immunotherapy; Mesothelioma; TNF

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; OROSOMUCOID; PHOSPHOLIPASE A2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATION; MALE; MALIGNANT MESOTHELIOMA; NEPHELOMETRY; PHASE 1 CLINICAL TRIAL; PLEURA FLUID; PRIORITY JOURNAL;

ACUTE-PHASE PROTEINS; AGED; C-REACTIVE PROTEIN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; OROSOMUCOID; PHOSPHOLIPASES A; PLEURAL NEOPLASMS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034053326     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00632.x     Document Type: Article

References (42)

1. 1 Selikoff IJ, Churg J, Hammond FC. Relations between exposure to asbestos and mesothelioma. New Engl J Med 1965;272:560-5.
2. 2 Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
3. 3 Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group Trial J Thorac Cardiovasc Surg 1991;102:1-9.
4. 4 Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres. J Clin Oncol 1988;6:527-35.
5. 5 Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.
6. 6 Curran D, Sahmoud T, Therasse P, Van Meerbeeck JP, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998;16:145-52.
7. 7 Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura, review of 123 patients. Cancer 1982;49:2431-5.
8. 8 Fitzpatrick DR, Manning LS, Musk AW, Robinson BWS, Bielefeldt-Ohmann H. Potential for cytokine therapy of malignant mesothelioma. Cancer Treatment Reviews 1995;21:273-88.
9. 9 Antman KH, Blum RH, Greenberber JS et al. Multimodality therapy for malignant mesothelioma on a study of natural history. Am J Med 1980;68:356-61.
10. 10 Boutin C, Viallat JR, Van Zandwijk N, Douillard JT, Paillard C, Guerin JC et al. Activity of intrapleural gamma-interferon in malignant mesothelioma. Cancer 1991;67: 2033-7.
11. 11 Markowitz A, Thielvoldt D, Yeomans A, Rubenstein E, Escalante C, Freimann K et al. Beneficial effects of intracavitary interferon-α2b (IFN): a phase I study in patients with ascites or pleural effusion. Proc Am Assoc Clin Oncol 1992;11:258.
12. 12 Yasumoto K, Miyazaki K, Nagashima et al. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987;47:2184-7.
13. 13 Eggermont AMM, Goey SH, Slingerland R, Jansen RLH, Oosterom R, Bolhuis RLH et al. Clinical and immunological evaluation of intrapleural administration of IL-2 in malignant pleural mesothelioma. A Phase I-II Study Proc Am Assoc Cancer Res 1991;32:206.
14. 14 Goey SH, Eggermont AMM, Punt CJA, Slingerland R, Gratama JW, Oosterom R et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995;72:1283-8.
15. 15 Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Guterman JM. A phase I trial of intravenously administered recombinant tumour necrosis factor alpha in cancer patients. J Clin Oncol 1988;6:1328-34.
16. 16 Spriggs DR, Sherman ML, Michie H et al. Recombinant human tumour necrosis factor administered as a 24h intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039-44.
17. 17 Eggermont AMM, Schraffordt Koops H, Liénard D, Kroon BBR, Van Geel AN, Hoekstra HJ et al. Isolated limb perfusion with high dose tumour necrosis factor-α in combination with IFNγ and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
18. 18 Liénard D, Eggermont AMM, Schraffordt Koops H, Kroon BBR, Rosenkaimer F, Autier P et al. Isolated perfusion of the limb with high dose tumour necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ) and melphalan for melanoma stage III. Results of a multi-center pilot study. Melanoma Res 1994;4:21-6.
19. 19 Reichman B, Markman M, Ianotti N et al. Phase I trial of intraperitoneal recombinant tumour necrosis factor. Proc Am Assoc Clin Oncol 1989;8:64 (Abstract).
20. 20 Hardy J, Jones A, Gore ME, Viner C, Selby B, Wiltshaw E. Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor. Eur J Cancer 1990;26:771-2.
21. 21 Karck U, Meerpohl HG, Pfleiderer A et al. TNF therapy of ascites and pleural effusion due to gynaecological carcinomas. J Cancer Res Clin Oncol 1990;116:328 (Abstract).
22. 22 Swaak AJG, Liénard D, Schraffordt Koops H, Lejeune FJ, Eggermont AMM. Effects of recombinant tumour necrosis factor (rTNF-α) in cancer. Observation on the acute-phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-α administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 1993;23:812-8.
23. 23 Todd NJ, Whicher JT, Westacott C, Gilbert A. The acute-phase protein response in mice does not show tolerance to recurrent sterile inflammation. Clin Chim Acta 1990;189:47-54.
24. 24 Whicher JT, Bell AM, Martin MFR, Marshall LA, Dieppe PA. Prostaglandins cause an increase in serum acute-phase proteins in man, which is diminished in systemic sclerosis. Clin Sci 1984;66:165-71.
25. 25 Yorston D, Whicher JT, Chambers R, Klouda P, Easty D. The acute-phase response in acute anterior uveitis. Trans Ophthalmol Soc UK 1985;104:166-70.
26. 26 Biró L, Domján Gy Falus A et al. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 1998;28:679-86.
27. 27 Butchart EG, Ashcroft T, Barsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 1976;31:15-24.
28. 28 World Health Organisation. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland:World Health Organisation; 1979.
29. 29 Van Kooten C, Rensink I, Pascal-Salcedo D, Van Oers R, Aarden LA. Monokine-production by human T-cells; IL-1α production restricted to memory T-cells. J Immunol 1991;146:2654-8.
30. 30 Helle M, Boeije L, De Groot ER, De Vos A, Aarden LA. Sensitive ELISA for interleukin 6. Detection of IL-6 in biological fluids and sera. J Immunol Methods 1991;138:42-56.
31. 31 Verbrugh CA, Hart MH, Aarden LA, Swaak AJG. Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions. Clin Rheumatol 1993;12:494-6.
32. 32 Wolbink GJ, Brouwer MC, Buysmann S, Ten Berge IJM, Hack CE. CRP-mediated activation of complement in vivo. Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996;157:473-9.
33. 2. Cancer Immunol Immunother 1995;41:287-92.
34. 34 Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-12.
35. 35 Monti G, Jaurand MC, Monnet I et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by γ-interferon treatment. Cancer Res 1994;54:4419-23.
36. 36 Schmitter D, Lauber B, Fagg B, Stahel RA. Heamatopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992;51:296-301.
37. 37 Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BW, Fitzpatrick DR. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 1995;40:241-50.
38. 38 Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990;12:1179-86.
39. 39 Knolle P, Lohr H, Treichel U, Dienes HP, Lohse A, Schlaack J et al. Parenchymal and nonparenchymal liver cells and their interaction in the local immune response. Z Gastroenterol 1995;33:613-20.
40. 40 Pullicino EA, Carli F, Poole S, Rafferty B, Malik ST, Elia M. The relationship between the circulating concentrations of interleukin 6 (IL-6, tumour necrosis factor (TNF) and the acute-phase response to elective surgery and accidental injury. Lymphokine Res 1990;9:231-8.
41. 41 Evans CA, Jellis J, Hughes SP, Remick DG, Friedland JS. Tumour necrosis factor-alpha, interleukin-6 and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuberculous osteomyelitis. J Infect Dis 1998;177:1582-7.
42. 42 Rauthe G, Sistermanns J. Recombinant tumour necrosis factor in the local therapy of malignant pleural effusion. Eur J Cancer 1997;33:226-31.